MedPage Today

Humira Clobbers Biosimilars in Battle for Part D Coverage

Just about every Medicare Part D prescription drug plan on offer this year covers the original version of adalimumab (Humira), whereas only about half will pay for any of the several biosimilar ...
Seeking Alpha

Adalimumab-adbm, Boehringer Ingelheim's Interchangeable biosimilar to Humira®, now available at low wholesale acquisition cost

RIDGEFIELD, Conn., Oct. 2, 2023 /PRNewswire/ -- Boehringer Ingelheim announced today that Adalimumab-adbm injection, the company's interchangeable* biosimilar to Humira ® (adalimumab), is now ...
Monthly Prescribing Reference

FDA Designates Yuflyma an Interchangeable Biosimilar to Humira

Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...
MedPage Today

Adalimumab Bests Conventional Therapy For Steroid Sparing in Uveitis

ORLANDO -- Adalimumab (Humira) was more effective than conventional immunosuppressive drugs at lowering or eliminating the need for corticosteroid use in patients with noninfectious uveitis, according ...
Medscape

Abbott pursues psoriatic arthritis, early-RA indications for adalimumab

Abbott Park, IL - Abbott Laboratories is seeking US and European regulatory approval to market its TNF inhibitor adalimumab (Humira) for the treatment of psoriatic arthritis (PsA) and as a first-line ...
Healio

FDA approves Abrilada as second interchangeable adalimumab biosimilar

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Abrilada as the second interchangeable biosimilar to adalimumab, according to a press ...
Seeking Alpha

RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed ...

NORTH CHICAGO, Ill., Oct. 20, 2025 /PRNewswire/ -- AbbVie (ABBV) today announced positive topline results from the Phase 3b/4 head-to-head SELECT-SWITCH study evaluating the efficacy and safety of ...
Business Wire

REPEAT/Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator

Autoinjector recognized by the Arthritis Foundation with Ease of Use Certification Individualized patient support program “HADLIMA For You” available including co-pay support Designed to improve ...
The American Journal of Managed Care

Stable Patient Satisfaction Found After Switching From Humira or Biosimilar Adalimumab to CT-P17

Switching to CT-P17 resulted in stable or increased patient satisfaction, especially for those previously on biosimilars or citrate-containing formulations. Patient education and shared ...
Healio

Adalimumab slashes Behçet’s uveitis relapse rate significantly more than cyclosporine

Please provide your email address to receive an email when new articles are posted on . Adalimumab plus corticosteroids significantly outperformed cyclosporine plus corticosteroids to delay Behçet’s ...
Business Wire

Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMA™ (adalimumab-bwwd) in Multiple Presentations Consistent with Originator

JERSEY CITY, N.J. & INCHEON, Korea--(BUSINESS WIRE)--Organon & Co. (NYSE: OGN) & Samsung Bioepis Co., Ltd. today announced that HADLIMA™ (adalimumab-bwwd), a biosimilar referencing Humira (adalimumab) ...